Granted Patent B2

US 12,453,724 · App. 19/174,612 · Granted Oct 28, 2025

Inventors: Charles D. Blizzard (Bedford, MA); Erica Kahn (Bedford, MA); Peter Jarrett (Bedford, MA); Rabia Gurses-Ozden (Bedford, MA); Rami El-Hayek (Bedford, MA); Elizabeth Braun (Bedford, MA); Joseph Iacona (Bedford, MA); Chintan Patel (Bedford, MA); Mark Ransbottom (Bedford, MA); Olivia Sherman (Bedford, MA); William Isom (Bedford, WA)

Assignee: OCULAR THERAPEUTIX, INC.

A61K31/4439A61K9/0051A61K47/34

Abstract

Claims (26)

1. A method of treating an ocular disease in a patient in need thereof, the treatment comprising administering to the patient's eye by intravitreal injection a sustained release biodegradable ocular implant comprising a hydrogel and axitinib, wherein the implant comprises axitinib polymorph IV in an amount of from about 400 μg to about 500 μg.

2. The method of claim 1 , wherein the ocular disease involves angiogenesis, neovascularization or a combination thereof.

3. The method of claim 1 , wherein the ocular disease is neovascular age-related macular degeneration (AMD), diabetic macular edema, diabetic retinopathy, or retinal vein occlusion.

4. The method of claim 1 , wherein the patient is a human patient.

5. The method of claim 4 , wherein final biodegradation of the hydrogel occurs within about 6 to about 9 months after injection.

6. The method of claim 4 , wherein the treatment period with one implant lasts for about 6 to about 12 months after administration.

7. The method of claim 4 , wherein a new implant is administered every 6 to 12 months.

8. The method of claim 4 , wherein the ocular disease is neovascular age-related macular degeneration (AMD).

9. The method of claim 1 , wherein the percentage of axitinib released from the implant in an in vitro test performed at 35° C.±0.5° C. in 0.01N HCl with 0.25% cetyl trimethyl ammonium bromide (CTAB) in a USP apparatus 4 is:

from about 10 to about 25% after 0.5 hours,

from about 30 to about 50% after 2 hours,

from about 60 to about 90% after 6 hours,

from about 79 to about 100% after 10 hours,

at least about 90% after 12 hours,

or at least about 92% after 16 hours.

10. The method of claim 1 , wherein the amount of axitinib released from the implant in an in vitro test performed at 35° C.±0.5° C. in 0.01N HCl with 0.25% cetyl trimethyl ammonium bromide (CTAB) in a USP apparatus 4 is:

from about 50 to about 80 μg after 0.5 hours,

from about 140 to about 200 μg after 2 hours,

from about 270 to about 360 μg after 6 hours,

from about 350 to about 450 μg after 10 hours,

or at least about 410 μg after 16 hours.

11. The method of claim 1 , wherein the implant has a composition on a dry basis (in % w/w) of about 30 to about 75% axitinib, about 20 to about 50% polyethylene glycol (PEG) units, and about 0.5 to about 15% sodium phosphate salt, and on a wet basis (in % w/w) of from about 5 to about 17% axitinib, about 4 to about 12% PEG units, and about 0.2 to about 5% sodium phosphate salt,

wherein the hydrogel comprises a PEG hydrogel network formed by crosslinking 4a20kPEG-SAZ and 8a20kPEG-NH 2 precursors,

wherein the implant in its dried state has a width of from about 0.20 to about 0.40 mm, and in its hydrated state (after 24 hours in PBS at a pH of 7.4 at 37° C.) has a length of about 11 mm or less,

and wherein the implant has a hydrated surface area of from about 10 to about 30 mm 2 , and wherein the ocular disease is neovascular age-related macular degeneration (AMD), diabetic macular edema, diabetic retinopathy, or retinal vein occlusion.

12. A method of treating an ocular disease in a patient in need thereof, the treatment comprising administering to the patient's eye by intravitreal injection a sustained release biodegradable ocular implant comprising a hydrogel and axitinib, wherein at least 90% by weight of the entire axitinib contained in the implant is polymorph IV.

Continuity (5)

References Cited (180)